Loading patent…
AssigneeHer Majesty the Queen in right of Canada, as represented by the Minister of Health
InventorsXuguang Li, Runtao He, Gary Van Domselaar
Estimating the term…
Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.
A method of preparing antibodies against influenza virus neuraminidase comprising inoculating an animal with an effective amount of a composition comprising an influenza neuraminidase peptide consisting of the amino acid sequence as set forth in SEQ ID No. 1 attached to a first end of a spacer, and a carrier protein attached to a second end of the spacer;
A method of preparing monoclonal antibodies against influenza virus neuraminidase comprising inoculating an animal with an effective amount of a composition comprising an influenza neuraminidase peptide consisting of the amino acid sequence as set forth in SEQ ID No. 1 attached to a first end of a spacer, and a carrier protein attached to a second end of the spacer;
Dependencies are inferred from the claim text.